[{"id":"1d4dd198-7dd9-44b5-bf2f-70642e346bc2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06400160","created_at":"2024-05-11T04:34:11.020Z","updated_at":"2024-07-02T16:35:05.740Z","phase":"Phase 1/2","brief_title":"Clinical Trial of TB511 in Advanced Solid Tumors","source_id_and_acronym":"NCT06400160","lead_sponsor":"Twinpig Biolab, Inc.","biomarkers":" CD8 • IFNG • TNFA • IL2RA • CD163 • PTPRC • IL2 • NCAM1 • IL10 • GZMB • ITGB2","pipe":" | ","alterations":" IL2-L","tags":["CD8 • IFNG • TNFA • IL2RA • CD163 • PTPRC • IL2 • NCAM1 • IL10 • GZMB • ITGB2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-05-06"}]